Cigna Reaches New 52-Week High (CI)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Cigna (NYSE: CI) hit a new 52-week high Wednesday as it is currently trading at $50.73, above its previous 52-week high of $50.67 with 2.8 million shares traded as of 3:30 p.m. ET. Average volume has been 2.3 million shares over the past 30 days.

Cigna has a market cap of $14.33 billion and is part of the health care sector and health services industry. Shares are up 18.3% year to date as of the close of trading on Tuesday.

CIGNA Corporation, a health services organization, through its subsidiaries, provides insurance and related products and services in the United States and internationally. The company has a P/E ratio of 11.1, below the average health services industry P/E ratio of 11.4 and below the S&P 500 P/E ratio of 17.7.

  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

TheStreet Ratings rates Cigna as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full Cigna Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

Snap and Coca-Cola Are Among 16 Stocks That Are Ready to Change Direction

Snap and Coca-Cola Are Among 16 Stocks That Are Ready to Change Direction

The Really Big Money Rushes to Super Bowl

The Really Big Money Rushes to Super Bowl

Big Pharma and the Sellers of Its Products Now Have a Problem

Big Pharma and the Sellers of Its Products Now Have a Problem

Managed Care Stocks Thrashed on Amazon News but Could Be Buying Opportunity

Managed Care Stocks Thrashed on Amazon News but Could Be Buying Opportunity

Can Buffett and a Couple of Rich Celebrity CEOs Really Fix Healthcare?

Can Buffett and a Couple of Rich Celebrity CEOs Really Fix Healthcare?